1. Time-to-Event Analysis of Polatuzumab Vedotin-Induced Peripheral Neuropathy to Assist in the Comparison of Clinical Dosing Regimens
- Author
-
Priya Agarwal, Jamie Hirata, Y-W Chu, W R Gillespie, Sandhya Girish, Dan Lu, Jin Yan Jin, L Leon, V Maiya, Chunze Li, and Matts Kågedal
- Subjects
0301 basic medicine ,medicine.medical_specialty ,Phases of clinical research ,Gastroenterology ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Internal medicine ,Medicine ,Pharmacology (medical) ,Dosing ,Survival analysis ,business.industry ,medicine.disease ,Polatuzumab vedotin ,Surgery ,030104 developmental biology ,Peripheral neuropathy ,Monomethyl auristatin E ,chemistry ,030220 oncology & carcinogenesis ,Modeling and Simulation ,Relative risk ,Rituximab ,business ,medicine.drug - Abstract
Polatuzumab vedotin, an antibody-drug conjugate containing monomethyl auristatin E, was associated with an incidence of grade ≥2 peripheral neuropathy (PN) of 55-72% in patients with indolent non-Hodgkin lymphoma in a phase II study, when dosed 1.8-2.4 mg/kg every 3 weeks until progression or for a maximum of 17 cycles. To quantify the correlation of conjugate exposure and treatment duration with PN risk, a time-to-event model was developed using data from phase I and II studies. The model suggested that PN risk increased with conjugate exposure and treatment cycles, and a trend for increased risk with body weight and albumin concentration. When capping the treatment duration to six to eight cycles, the risk ratio of a dose of 2.4 mg/kg vs. 1.8 mg/kg was ≥1.29; the predicted incidence of grade ≥2 PN at 1.8-2.4 mg/kg dose levels was 17.8-37.2%, which is comparable with other antimicrotubule agents for lymphoma treatment.
- Published
- 2017
- Full Text
- View/download PDF